Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity
Checkpoint inhibitors targeting the PD-1/PD-L1 axis have revolutionized cancer immunotherapy, yet response rates remain limited. To enhance efficacy, next-generation approaches target T cell-activating cytokines to PD-1 via antibodies. The goal is simultaneous checkpoint blockade and cytokine potent...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2025-12-01
|
| Schriftenreihe: | Frontiers in Immunology |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1718321/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|